Study guide

7.3 Chimeric Antigen Receptor (CAR) T-Cell Therapies & Cellular Logistics

BCOP Board Certified Oncology Pharmacist Exam

Track your progress as you read

Finished sections get a check mark.

1 Chapter 1: Introduction & BCOP Exam Foundations

1.1 BCOP Exam Specifications, Passing Standard & Eligibility 1.2 The Clinical Oncology Pharmacist Scope of Practice & Core Competencies 1.3 Study Guide Methodology & Active Learning Strategy

2 Chapter 2: Cancer Biology & Pathophysiology

2.1 Hallmarks of Cancer, Multi-Step Carcinogenesis & Tumor Microenvironment 2.2 Cell Cycle Checkpoints, Apoptotic Pathways & DNA Damage Repair Mechanics 2.3 Tumor Immunology, Antigen Presentation & Mechanisms of Immune Evasion

3 Chapter 3: Genomic Biomarkers & Molecular Targets

3.1 Somatic vs Germline Mutations, NGS Profiling & Variant Classification 3.2 Actionable Oncogenic Driver Mutations & Targeted Kinase Inhibitors 3.3 Pharmacogenomics in Oncology: DPYD, TPMT, NUDT15, UGT1A1 & CYP2D6

4 Chapter 4: Diagnostics, Staging & Clinical Assessment

4.1 Circulating Tumor Markers, Flow Cytometry & Diagnostic Modalities 4.2 TNM Staging Systems, Histopathologic Grading & Hematologic Prognostic Indices 4.3 Performance Status Scales & Organ Function Assessment 4.4 Cancer Screening, Early Detection & Prevention

5 Chapter 5: Cytotoxic Chemotherapy Pharmacology & Regimens

5.1 Alkylating Agents & Platinum Analogs 5.2 Antimetabolites & Folate Antagonists 5.3 Topoisomerase Inhibitors, Anthracyclines & Cardiotoxicity Mitigation 5.4 Antimicrotubule Agents: Taxanes, Vinca Alkaloids & Halichondrins

6 Chapter 6: Targeted Small-Molecule Therapies

6.1 Small-Molecule Tyrosine Kinase Inhibitors in Solid Tumors 6.2 Hematologic Small-Molecule Kinase Inhibitors 6.3 Pathway-Specific Inhibitors: PARP, CDK4/6, BCL-2 & PI3K/AKT/mTOR Pathways

7 Chapter 7: Immunotherapy, Biologics & Cellular Therapy

7.1 Immune Checkpoint Inhibitors & irAE Management 7.2 Naked Monoclonal Antibodies, Antibody-Drug Conjugates & Bispecific T-Cell Engagers 7.3 Chimeric Antigen Receptor (CAR) T-Cell Therapies & Cellular Logistics

8 Chapter 8: Breast & Gynecologic Malignancies

8.1 Early-Stage & Locoregional Breast Cancer 8.2 Advanced & Metastatic Breast Cancer Targeted Strategies 8.3 Epithelial Ovarian, Endometrial & Cervical Malignancies

9 Chapter 9: Thoracic & Skin Malignancies

9.1 Early & Locally Advanced NSCLC & Small Cell Lung Cancer 9.2 Metastatic Non-Small Cell Lung Cancer (Driver-Positive and Driver-Negative) 9.3 Cutaneous Melanoma & Non-Melanoma Skin Cancers

10 Chapter 10: Gastrointestinal & Genitourinary Malignancies

10.1 Colorectal Cancer: Staging, Adjuvant Therapy, and Biomarker-Driven Metastatic Therapeutics 10.2 Esophagogastric, Pancreatic, and Hepatobiliary Malignancies 10.3 Genitourinary Malignancies: Prostate, Renal Cell, and Urothelial Carcinomas

11 Chapter 11: Hematologic Malignancies: Leukemias & Myeloma

11.1 Acute Myeloid & Acute Lymphoblastic Leukemias 11.2 Chronic Leukemias & Myeloproliferative Neoplasms 11.3 Multiple Myeloma & Plasma Cell Dyscrasias 11.4 Non-Malignant Hematologic Disorders: ITP, Aplastic Anemia, Sickle Cell Disease & TTP

12 Chapter 12: Lymphomas & Stem Cell Transplantation

12.1 Classical Hodgkin Lymphoma: Staging, Frontline Regimens & Relapsed/Refractory Strategies 12.2 Non-Hodgkin Lymphomas: Aggressive, Indolent, Mantle Cell & T-Cell Subtypes 12.3 Hematopoietic Stem Cell Transplantation, Complications & Graft-versus-Host Disease

13 Chapter 13: Supportive Care & Toxicity Management

13.1 Chemotherapy-Induced Nausea and Vomiting (CINV) Prophylaxis & Rescue 13.2 Myelosuppression, Febrile Neutropenia & Growth Factor Stewardship 13.3 Oncologic Emergencies: TLS, Hypercalcemia, Spinal Cord Compression & SVCS 13.4 Chemotherapy Extravasation, Organ Protectants & Antidotes

14 Chapter 14: Hazardous Drug Handling & Compounding Safety

14.1 USP <800> & NIOSH Hazardous Drug Standards 14.2 Engineering Controls, Personal Protective Equipment & Closed System Transfer Devices 14.3 Safe Handling, Surface Decontamination & Accidental Spill Response

15 Chapter 15: Chemotherapy Safety, Dosing & Order Verification

15.1 Regimen Standardization, Dose Calculation Formulas & Organ Adjustments 15.2 Independent Double-Check, Verification Checkpoints & Toxicity Gating 15.3 Oral Chemotherapy Management, Adherence & Specialty Pharmacy Coordination

16 Chapter 16: Clinical Trials, Biostatistics & Evidence Evaluation

16.1 Oncology Clinical Trial Designs, Endpoints & Statistical Power 16.2 Biostatistical Concepts: Hazard Ratios, Survival Analysis & Precision Metrics 16.3 Evidence Synthesis, Guideline Hierarchy & Critical Literature Appraisal

17 Chapter 17: Health Systems, Regulatory Compliance & Patient Education

17.1 Oncology Formulary Management, Biosimilars & Value Frameworks 17.2 Regulatory Mandates, REMS Programs & Investigational Drug Services 17.3 Patient & Caregiver Counseling, Survivorship Care & Palliative Ethics 17.4 Complementary, Alternative & Integrative Therapies in Oncology

7.3 Chimeric Antigen Receptor (CAR) T-Cell Therapies & Cellular Logistics

Key Takeaways Explain This Topic AI

Second-generation CAR T-cell designs incorporate an extracellular scFv antigen recognition domain, a CD3-zeta intracellular signaling endodomain, and a critical costimulatory domain: CD28 costimulation (axi-cel, brexu-cel) drives rapid, explosive glycolytic expansion with earlier peak CRS/ICANS, whereas 4-1BB/CD137 costimulation (tisa-cel, liso-cel, ide-cel, cilta-cel) promotes mitochondrial oxidative metabolism, tonic persistence, and delayed toxicity kinetics.

Lymphodepleting conditioning with Fludarabine (30 mg/m^2/day x 3 days) plus Cyclophosphamide (300–500 mg/m^2/day x 3 days) eliminates immunosuppressive regulatory T cells and cytokine sinks (IL-2, IL-7, IL-15), creating a hospitable niche for robust CAR T-cell engraftment; fludarabine requires a 40% dose reduction for CrCl 30–49 mL/min and avoidance/substitution with bendamustine for CrCl < 30 mL/min.

Cytokine Release Syndrome (CRS) is graded according to ASTCT consensus criteria by fever, hypotension, and hypoxia: Grade 1 requires supportive care, Grade 2 (fluid-responsive hypotension or low-flow oxygen) triggers Tocilizumab (8 mg/kg IV, up to 4 doses total), and Grade >= 3 (vasopressor-dependent hypotension or high-flow oxygen/intubation) mandates Tocilizumab combined with high-dose corticosteroids (dexamethasone or methylprednisolone).

Immune Effector Cell-Associated Neurotoxicity Syndrome (ICANS) is monitored via the 10-point ICE score and handwriting assessments; Tocilizumab is INEFFECTIVE for isolated ICANS because it does not cross the blood-brain barrier and can worsen CNS toxicity by displacing peripheral IL-6 into the circulation, making Systemic Corticosteroids (Dexamethasone 10–20 mg IV Q6H or pulse methylprednisolone) the undisputed gold standard for ICANS management.

FDA REMS mandates ensure at least 2 doses of tocilizumab are on-site prior to infusion, enforce patient proximity within 2 hours of the certified treatment center for at least 4 weeks, and prohibit driving/operating heavy machinery for 8 weeks post-infusion; supportive care includes mandatory PJP/antiviral prophylaxis and monthly IVIG replacement for hypogammaglobulinemia (IgG < 400 mg/dL).

Last updated: August 2026

7.3 Chimeric Antigen Receptor (CAR) T-Cell Therapies & Cellular Logistics

Chimeric Antigen Receptor (CAR) T-cell therapy represents a revolutionary convergence of gene therapy, cellular immunotherapy, and precision oncology. Autologous T lymphocytes harvested from a patient are genetically engineered ex vivo using viral vectors (lentivirus or gamma-retrovirus) to express a synthetic, recombinant receptor that redirects their cytolytic machinery against specific cell-surface tumor antigens in an MHC-independent manner .

Commercial CAR T-cell therapies have established curative-intent paradigms in relapsed/refractory B-cell Acute Lymphoblastic Leukemia (B-ALL) , Large B-Cell Lymphomas (LBCL) , Mantle Cell Lymphoma (MCL) , Follicular Lymphoma (FL) , and Multiple Myeloma (MM) . Clinical oncology pharmacists are essential across the entire cellular therapy continuum—from evaluating renal pharmacokinetics during lymphodepletion conditioning to intercepting life-threatening Cytokine Release Syndrome (CRS) , Immune Effector Cell-Associated Neurotoxicity Syndrome (ICANS) , prolonged cytopenias, and secondary immunodeficiencies.

1. CAR Structural Biology & Costimulatory Signaling Kinetics

A chimeric antigen receptor consists of four modular structural components:

Extracellular Antigen-Binding Domain: A single-chain variable fragment ( scFv ) derived from the variable light (V_L) and variable heavy (V_H) chains of a monoclonal antibody joined by a flexible peptide linker. Recognizes intact cell-surface antigens without requiring processing or presentation by Major Histocompatibility Complex (MHC) molecules.

Hinge / Spacer Region: Extracellular structural domain (typically derived from CD8-alpha or IgG Fc) that provides physical reach, rotational flexibility, and optimal spatial orientation to access the target epitope.

Transmembrane Domain: Anchors the receptor within the T-cell lipid bilayer (derived from CD8-alpha or CD28).

Intracellular Signaling Endodomain: Comprises the CD3-zeta signaling chain (containing 3 Immunoreceptor Tyrosine-based Activation Motifs [ITAMs]) fused to one or more intracellular costimulatory domains . +-----------------------------------------------------------------------------+

  • | CAR T-CELL GENERATIONAL ARCHITECTURE |
  • | |
  • | [1ST GENERATION] [2ND GENERATION] [3RD GENERATION] |
  • | - scFv + Hinge + TM - scFv + Hinge + TM - scFv + Hinge + TM |
  • | - CD3-zeta endodomain only - CD3-zeta + ONE - CD3-zeta + TWO |
  • | - Clinical Result: Rapid Costimulatory Domain Costimulatory |
  • | anergy, poor expansion, (CD28 OR 4-1BB) Domains |
  • | lack of persistence. - Standard of Care in (e.g., CD28 + 4-1BB)|
  • | all FDA products! |
  • +-----------------------------------------------------------------------------+

CD28 vs. 4-1BB Costimulatory Domain: Metabolic & Clinical Kinetics +-----------------------------------------------------------------------------+

  • | CD28 VS. 4-1BB COSTIMULATION COMPARISON |
  • | |
  • | FEATURE CD28 DOMAIN 4-1BB (CD137) DOMAIN |
  • | ----------------------------------------------------------------------- |
  • | Commercial Agents Axi-cel, Brexu-cel Tisa-cel, Liso-cel, |
  • | Ide-cel, Cilta-cel |
  • | Intracellular Signal PI3K / AKT / mTOR TRAF1/2/3 -> NF-kappaB |
  • | Cellular Metabolism Aerobic Glycolysis Mitochondrial Fatty Acid |
  • | (Effector Memory) Oxidation (Central Memory)|
  • | Expansion Kinetics Rapid, explosive peak Progressive, tonic, |
  • | surge within 7-10 days gradual expansion |
  • | T-Cell Persistence Shorter (months) Prolonged (years) |
  • | Median CRS Onset Day 1 to 2 post-infusion Day 4 to 9 post-infusion |
  • | Median ICANS Onset Day 4 to 5 post-infusion Day 6 to 11 post-infusion |
  • | Peak Cytokine Levels Higher peak surge Lower, blunted peak |
  • +-----------------------------------------------------------------------------+

2. FDA-Approved CAR T-Cell Products Master Comparison +-----------------------------------------------------------------------------+

  • | FDA-APPROVED CAR T-CELL MASTER CLINICAL MATRIX |
  • +-----------------------------------------------------------------------------+
  • | 1. TISAGENLECLEUCEL (Tisa-cel / Kymriah) |
  • | - Target: CD19 | Costimulatory Domain: 4-1BB | Vector: Lentivirus |
  • | - Indications: R/R B-ALL (age <= 25 years per ELIANA trial; CR ~82%), |
  • | R/R DLBCL (JULIET trial), R/R Follicular Lymphoma (ELARA trial). |
  • |-----------------------------------------------------------------------------|
  • | 2. AXICABTAGENE CILOLEUCEL (Axi-cel / Yescarta) |
  • | - Target: CD19 | Costimulatory Domain: CD28 | Vector: Retrovirus |
  • | - Indications: 2nd-line R/R Large B-Cell Lymphoma (ZUMA-7 trial: superior|
  • | EFS and OS vs standard platinum salvage + autologous transplant), |
  • | 3rd-line+ R/R LBCL (ZUMA-1), R/R Follicular Lymphoma (ZUMA-5). |
  • | - Toxicity Profile: High peak CRS (90%, G3+ 10-15%) & ICANS (60%, G3+ 25%)|
  • |-----------------------------------------------------------------------------|
  • | 3. BREXUCABTAGENE AUTOLEUCEL (Brexu-cel / Tecartus) |
  • | - Target: CD19 | Costimulatory Domain: CD28 | Vector: Retrovirus |
  • | - Indications: R/R Mantle Cell Lymphoma (ZUMA-2), R/R adult B-ALL (ZUMA-3)|
  • | - Manufacturing Feature: Incorporates an ex vivo T-cell enrichment step |
  • | that separates circulating malignant CD19+ blasts from normal T cells, |
  • | preventing premature CAR T-cell exhaustion during manufacturing. |
  • |-----------------------------------------------------------------------------|
  • | 4. LISOCABTAGENE MARALEUCEL (Liso-cel / Breyanzi) |
  • | - Target: CD19 | Costimulatory Domain: 4-1BB | Vector: Lentivirus |
  • | - Indications: 2nd-line and 3rd-line+ LBCL (TRANSFORM), R/R CLL, MCL, FL |
  • | - Formulation: Administered as a DEFINED 1:1 RATIO OF CD4+ TO CD8+ CAR |
  • | T cells (infused as two separate sequential components) to optimize |
  • | potency while minimizing toxicity variability. |
  • |-----------------------------------------------------------------------------|
  • | 5. IDECABTAGENE VICLEUCEL (Ide-cel / Abecma) |
  • | - Target: BCMA | Costimulatory Domain: 4-1BB | Vector: Lentivirus |
  • | - Indication: Relapsed/refractory Multiple Myeloma post >= 2 prior lines |
  • | (KarMMa, KarMMa-3 trials). Target dose: 300 to 460 x 10^6 CAR T cells. |
  • |-----------------------------------------------------------------------------|
  • | 6. CILTACABTAGENE AUTOLEUCEL (Cilta-cel / Carvykti) |
  • | - Target: BCMA | Costimulatory Domain: 4-1BB | Vector: Lentivirus |
  • | - Indication: Relapsed/refractory Multiple Myeloma (CARTITUDE trials; |
  • | exceptional ORR >95%, CR >80%). |
  • | - Structural Feature: BIVALENT SINGLE-DOMAIN VHH ANTIBODIES targeting |
  • | two distinct epitopes on BCMA, conferring high binding avidity. |
  • | - Unique Late Toxicity: DELAYED NEUROTOXICITY / PARKINSONIAN MOVEMENT |
  • | DISORDERS (MNT) occurring 2 to 8 weeks post-infusion (resting tremor, |
  • | masked facies, bradykinesia, cognitive changes; poor steroid response). |
  • +-----------------------------------------------------------------------------+
  • 3. End-to-End Clinical Logistics & Lymphodepleting Chemotherapy

The autologous CAR T-cell treatment journey spans several distinct phases requiring close multidisciplinary coordination: +-----------------------------------------------------------------------------+

  • | CAR T-CELL CELLULAR WORKFLOW TIMELINE |
  • | |
  • | [STEP 1: PATIENT SELECTION & LEUKAPHERESIS] |
  • | - Peripheral blood mononuclear cells (PBMCs) harvested via leukapheresis |
  • | - Avoid prolonged lymphodepleting agents (e.g., bendamustine, purine |
  • | analogs) for >= 4-6 weeks prior to preserve T-cell fitness |
  • | | |
  • | v |
  • | [STEP 2: BRIDGING THERAPY & MANUFACTURING WINDOW (3-5 WEEKS)] |
  • | - Systemic chemo/targeted therapy or focal radiation to control tumor |
  • | bulk and prevent rapid progression while cells are manufactured ex vivo |
  • | | |
  • | v |
  • | [STEP 3: LYMPHODEPLETING CONDITIONING CHEMOTHERAPY] |
  • | - Fludarabine 30 mg/m^2/day IV x 3 days (Days -5, -4, -3) |
  • | - Cyclophosphamide 300-500 mg/m^2/day IV x 3 days (Days -5, -4, -3) |
  • | - Days -2 and -1: Rest days (allow chemotherapy clearance) |
  • | | |
  • | v |
  • | [STEP 4: INFUSION PROTOCOL (DAY 0)] |
  • | - Verify institutional pharmacy inventory: >= 2 DOSES TOCILIZUMAB ON-SITE |
  • | - Premedication 30-60 min prior: Acetaminophen 650 mg PO + Diphenhydramine|
  • | 25-50 mg IV/PO. STRICTLY AVOID PROPHYLACTIC CORTICOSTEROIDS! |
  • | - Thaw product at bedside in 37 deg C water bath; infuse via non-filtered |
  • | tubing without leukocyte reduction filters within 30 minutes |
  • +-----------------------------------------------------------------------------+
  • Pharmacologic Rationale for Lymphodepleting Conditioning

Lymphodepleting chemotherapy with fludarabine and cyclophosphamide serves three critical physiological functions:

Elimination of Immunosuppressive Elements: Eradicates host Regulatory T cells (Tregs) and Myeloid-Derived Suppressor Cells (MDSCs).

Ablation of Endogenous Cytokine Sinks: Destroys recipient lymphocytes that consume homeostatic cytokines ( IL-2, IL-7, IL-15 ), causing a profound serum surge of these cytokines that promotes exponential CAR T-cell expansion.

Upregulation of Adhesion Molecules: Induces tumor-cell expression of costimulatory ligands and increases accessibility for cellular trafficking.

Renal Dose Adjustments for Lymphodepletion

Fludarabine: Approximately 60% of the active circulating metabolite (2-fluoro-ara-A) is eliminated unchanged by renal excretion. Failure to adjust fludarabine for renal dysfunction leads to severe systemic accumulation, irreversible neurotoxicity (leukoencephalopathy, coma, blindness), and prolonged marrow aplasia.

CrCl >= 80 mL/min: 100% dose (30 mg/m^2/day x 3 days).

CrCl 50–79 mL/min: Reduce dose by 20% (24 mg/m^2/day x 3 days).

CrCl 30–49 mL/min: Reduce dose by 40% (18 mg/m^2/day x 3 days).

CrCl < 30 mL/min: Fludarabine is contraindicated. Utilize Bendamustine 90 mg/m^2/day IV x 2 days (Days -4, -3) as an evidence-based alternative lymphodepletion regimen.

4. ASTCT Consensus Grading & Management of CRS and ICANS

The American Society for Transplantation and Cellular Therapy (ASTCT) established standardized consensus grading systems for Cytokine Release Syndrome (CRS) and Immune Effector Cell-Associated Neurotoxicity Syndrome (ICANS). +-----------------------------------------------------------------------------+

  • | ASTCT CRS GRADING & MANAGEMENT |
  • | |
  • | CRS GRADING DEFINITIONS (Must include Fever >= 38.0 deg C): |
  • | - GRADE 1: Fever >= 38.0 deg C; NO hypotension; NO hypoxia. |
  • | * Treatment: Supportive care, antipyretics (APAP), IV fluids, blood |
  • | cultures, empiric broad-spectrum antibiotics (cefepime). |
  • | - GRADE 2: Fever >= 38.0 deg C + Hypotension NOT requiring vasopressors |
  • | (fluid-responsive) AND/OR Hypoxia requiring Low-Flow Nasal Cannula |
  • | (<= 40% FiO2 or <= 6 L/min). |
  • | * Treatment: TOCILIZUMAB 8 mg/kg IV (max 800 mg; repeat Q8H, max 4 doses|
  • | total). Add Dexamethasone 10 mg IV Q6H if no rapid response. |
  • | - GRADE 3: Fever >= 38.0 deg C + Hypotension requiring ONE Vasopressor |
  • | (+/- vasopressin) AND/OR Hypoxia requiring High-Flow Nasal Cannula, |
  • | facemask, or non-rebreather. |
  • | * Treatment: TOCILIZUMAB 8 mg/kg IV PLUS DEXAMETHASONE 10-20 mg IV Q6H |
  • | (or Methylprednisolone 1-2 mg/kg/day). ICU transfer. |
  • | - GRADE 4: Fever >= 38.0 deg C + Hypotension requiring MULTIPLE |
  • | Vasopressors (excluding vasopressin) AND/OR Hypoxia requiring Positive |
  • | Pressure (CPAP, BiPAP, mechanical intubation). |
  • | * Treatment: TOCILIZUMAB 8 mg/kg IV PLUS HIGH-DOSE PULSE METHYLPRED- |
  • | NISOLONE 1,000 mg IV daily x 3 days. Refractory: ANAKINRA (IL-1R |
  • | antagonist) 100-200 mg SC/IV Q6-12H or SILTUXIMAB 11 mg/kg IV. |
  • +-----------------------------------------------------------------------------+
  • ASTCT ICANS Grading & The ICE Scoring Tool

ICANS is evaluated using the 10-point Immune Effector Cell Encephalopathy (ICE) assessment tool:

Orientation (4 points): Year, month, city, hospital.

Naming (3 points): Name 3 common objects (e.g., pen, cup, watch).

Following Commands (1 point): (e.g., "Touch your nose with your left thumb").

Writing (1 point): Write a complete, coherent standard sentence.

Attention (1 point): Count backward from 100 by 10s (100, 90, 80, 70...). +-----------------------------------------------------------------------------+

  • | ASTCT ICANS GRADING & MANAGEMENT |
  • | |
  • | ICANS GRADING DEFINITIONS: |
  • | - GRADE 1: ICE score 7-9 OR mild somnolence (awakens spontaneously). |
  • | * Treatment: Supportive care, ICE score Q4H, seizure prophylaxis. |
  • | - GRADE 2: ICE score 3-6 OR moderate somnolence (awakens to voice). |
  • | * Treatment: DEXAMETHASONE 10 mg IV Q6H until Grade <= 1, then taper. |
  • | - GRADE 3: ICE score 0-2 OR severe somnolence (awakens only to tactile) |
  • | OR any clinical seizure (non-status) OR focal cerebral edema on CT/MRI. |
  • | * Treatment: DEXAMETHASONE 10-20 mg IV Q6H or Methylpred 1-2 mg/kg/day. |
  • | - GRADE 4: ICE score 0 (patient unarousable) OR status epilepticus OR |
  • | diffuse cerebral edema / herniation OR decerebrate/decorticate posturing|
  • | * Treatment: PULSE METHYLPREDNISOLONE 1,000 mg IV daily x 3 days PLUS |
  • | Anakinra 100-200 mg IV Q6-8H. Emergent hyperventilation/osmotic therapy|
  • | |
  • | [CRITICAL BCOP PHARMACY PEARL: TOCILIZUMAB IN ISOLATED ICANS] |
  • | - Tocilizumab is an intact mAb (~150 kDa) that DOES NOT CROSS the blood- |
  • | brain barrier in therapeutic concentrations. |
  • | - In isolated ICANS without concurrent systemic CRS, TOCILIZUMAB IS NOT |
  • | RECOMMENDED. Competitive blockade of peripheral IL-6 receptors can |
  • | transiently increase free circulating serum IL-6, which diffuses across |
  • | a disrupted blood-brain barrier and WORSENS neurocognitive toxicity! |
  • | - SYSTEMIC CORTICOSTEROIDS ARE THE PRIMARY STANDARD OF CARE FOR ICANS. |
  • +-----------------------------------------------------------------------------+
  • Seizure Prophylaxis Protocols

Mandatory baseline seizure prophylaxis with Levetiracetam (Keppra) 500–750 mg PO/IV BID initiated on Day 0 (or during lymphodepletion) and continued for >= 30 days post-infusion .

Routine EEG surveillance and diagnostic neuroimaging (MRI brain) for any Grade >= 2 ICANS or sudden neurological deterioration.

5. Post-Infusion Complications, FDA REMS, and Supportive Care +-----------------------------------------------------------------------------+

  • | POST-INFUSION TOXICITIES & SUPPORTIVE PROTOCOLS |
  • | |
  • | 1. ON-TARGET OFF-TUMOR B-CELL APLASIA & HYPOGAMMAGLOBULINEMIA |
  • | - CD19/BCMA targeting destroys normal healthy B cells and plasma cells.|
  • | - Serum IgG levels fall below 400 mg/dL. |
  • | - Management: Administer INTRAVENOUS IMMUNOGLOBULIN (IVIG) 400-500 |
  • | mg/kg IV every 3 to 4 weeks for serum IgG < 400-500 mg/dL in patients|
  • | with recurrent or severe sinopulmonary infections. |
  • | |
  • | 2. PROLONGED BIPHASIC CYTOPENIAS |
  • | - Grade 3/4 neutropenia and thrombocytopenia persisting past Day +28 |
  • | (mediated by bone marrow stromal inflammation and clonal T-cell surge)|
  • | - Avoid G-CSF during active CRS/ICANS (fuels macrophage activation); |
  • | G-CSF may be cautiously initiated after acute toxicities resolve. |
  • | - Refractory: Thrombopoietin agonists (eltrombopag) or autologous stem |
  • | cell boost. |
  • | |
  • | 3. ANTIMICROBIAL PROPHYLAXIS STANDARDS |
  • | - PJP Prophylaxis: TMP-SMX 1 DS tab PO 3x/week for >= 6 months post- |
  • | infusion and until CD4+ T-cell count > 200 cells/mcL. |
  • | - Antiviral Prophylaxis: Acyclovir 400 mg PO BID or Valacyclovir 500 mg|
  • | PO daily for >= 6 months post-infusion (prevent HSV/VZV reactivation)|
  • | - Antifungal: Fluconazole or posaconazole during absolute neutropenia. |
  • | |
  • | 4. FDA REMS REQUIREMENTS & DISCHARGE MANDATES |
  • | - Certified healthcare facilities only with verified REMS training. |
  • | - Confirmed pharmacy inventory: >= 2 DOSES TOCILIZUMAB ON-SITE. |
  • | - Patient Proximity: Must remain within 2 HOURS / 100 MILES of the |
  • | certified CAR T medical center for at least 4 WEEKS (28 days). |
  • | - Driving Restriction: STRICTLY PROHIBITED FROM DRIVING or operating |
  • | heavy machinery for at least 8 WEEKS post-infusion. |
  • +-----------------------------------------------------------------------------+